Trauma-Sensitive Yoga for Female Veterans With PTSD Who Experienced Military Sexual Trauma (PSL II)

October 11, 2022 updated by: VA Office of Research and Development

Trauma-sensitive Yoga for Female Veterans With PTSD Who Experienced Military Sexual Trauma

In this study, we are evaluating the effectiveness of a yoga intervention to treat posttraumatic stress disorder (PTSD), its associated symptoms of chronic pain and insomnia, and biological and physiological responses to trauma and PTSD in women Veterans who experienced military sexual trauma (MST). If effective, this yoga intervention could reduce PTSD symptoms and chronic pain, improve sleep quality, and decrease the body's automatic "fight or flight" stress response and the damage this stress response causes in the body, including heart disease and diabetes. This intervention could improve these women Veterans' quality of life and social functioning, for example, going to work and having satisfying relationships with family and friends. This study may support an innovative, complementary and alternative PTSD treatment for women Veterans who experienced MST. This new, evidence-based PTSD treatment could supplement current PTSD treatments. Clinical guidelines for this yoga intervention could be implemented nationally in the VA health care system.

Study Overview

Detailed Description

Objectives: The overall goal of this project is to maximize the health, social functioning, and quality of life of women Veterans with posttraumatic stress disorder (PTSD) who have experienced military sexual trauma (MST). The specific aims of this randomized controlled trial (RCT) are to evaluate the effectiveness of a trauma-sensitive yoga intervention designed specifically for women who experienced sexual trauma as compared to a gold-standard PTSD treatment, Cognitive Processing Therapy, to 1) treat PTSD and its co-morbid symptoms of chronic pain and insomnia, 2) improve social functioning and quality of life, and 3) reduce the biological and psychophysiologic responses associated with PTSD in women Veterans who experienced MST.

Research Plan: This five year RCT is the next step following the NRI Pilot Study (NRI 12-417) in which the investigators demonstrated the feasibility of recruitment, retention, randomization, intervention implementation, and data collection, including biological and psychophysiological data. Women Veterans seeking treatment for PTSD were recruited from a primary site (southeast US) and second site (northwest US) and were randomized to Trauma Center Trauma-Sensitive Yoga (TCTSY) (10 weekly sessions) or Cognitive Processing Therapy (CPT) (12 weekly sessions); both intervention protocols are data-driven. The target enrollment sample size is 210, with a target final sample of 100 or more. The investigators are conservatively allowing for 50%-60% retention, based on pilot study results.

Methods: Data Collection: Data are collected at four points, baseline through 3-months post-intervention. Outcome measures include self-report, clinical assessments and biologic and psychophysiologic markers. Specific outcomes include PTSD symptom severity, chronic pain, insomnia, social functioning, quality of life, cytokines (IL-6, IL-10), C-reactive protein, heart rate variability, and dark-enhanced startle. Data Analysis: Comparisons between the groups at baseline will be run using t-tests, Mann Whitney non-parametric tests, and chi-square tests as appropriate. Multilevel mixed models (MLM) will be used to analyze the differences between the groups over time. MLM adjusts for attrition (missing data) over time and applies appropriate correlation structure between the time points.

Clinical Relevance: Women Veterans experience MST and PTSD at alarming rates; consistently reported prevalence rates for both among VHA patient samples are 20% or more. MST and PTSD put this population at risk for significant physical and mental health symptoms, including chronic pain, suicide, and negative health behaviors. This RCT may provide sufficient evidence to support an innovative, complementary and alternative PTSD treatment for women Veterans who experienced MST. The positive effects of reducing distressing symptoms and PTSD-related psychophysiological stress would likely improve social functioning and quality of life and minimize the significant medical consequences of PTSD in this population. This new, evidence-based PTSD treatment could supplement existing evidence-based PTSD treatment modalities. Clinical guidelines for this innovative intervention based on evidence from this clinical trial could be disseminated to and implemented in VA Medical Centers nationwide.

Study Type

Interventional

Enrollment (Actual)

200

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Georgia
      • Decatur, Georgia, United States, 30033
        • Atlanta VA Medical and Rehab Center, Decatur, GA
    • Oregon
      • Portland, Oregon, United States, 97239
        • VA Portland Health Care System, Portland, OR

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Women Veterans who experienced MST
  • Diagnosed with PTSD related to MST
  • Insomnia
  • Willing to participate in either TCTSY or CPT study intervention

Exclusion Criteria:

  • Schizophrenia with significant psychotic symptoms
  • Current, active suicidal intent or plan
  • Current substance abuse or dependence
  • Certain medical conditions that can contribute significantly to psychiatric symptoms, including:

    • poorly controlled hypo/hyperthyroidism
    • kidney or liver failure
  • Dementia
  • Moderate or severe traumatic brain injury (TBI) or other cognitive impairment sufficient to interfere with ability to give informed consent
  • Pain due to acute injury (<3 months), post-surgical pain (<3 months) or pain due to malignancy; pain related to injury and surgery are excluded to reduce risk of exacerbating underlying injury
  • Receiving mental health treatment outside of the VA
  • Ongoing participation in mental health treatment at odds with study intervention (For Example: yoga, trauma-focused treatment)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Trauma Center Trauma-Sensitive Yoga (TCTSY)
10-weekly 1-hour TCTSY Sessions
(10) 1-hour sessions of trauma sensitive yoga
Active Comparator: Cognitive Processing Therapy (CPT)
12-weekly 1.5 hour CPT Sessions
(12) 1.5 hour sessions of cognitive processing therapy
Other Names:
  • Cognitive Processing Therapy-Cognitive

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Determine the effectiveness of TSY compared to CPT over time in reducing PTSD symptoms, chronic pain, and insomnia
Time Frame: Baseline; Mid-Treatment (TSY, 5 weeks: CPT, 6 weeks); 2-Weeks Post-Treatment; 3-Months Post-Treatment
Participants in the TSY group will show statistically and clinically meaningful reductions in PTSD symptoms, chronic pain and insomnia, Clinician Administered PTSD Scale (CAPS) scores, PTSD Checklist-5 (PCL-5) scores, Brief Pain Inventory (BPI) scores, Pittsburgh Sleep Quality Index (PSQI) scores) compared to CPT group results following treatment.
Baseline; Mid-Treatment (TSY, 5 weeks: CPT, 6 weeks); 2-Weeks Post-Treatment; 3-Months Post-Treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To evaluate the effectiveness of TSY as compared to CPT over time in improving quality of life and social functioning in women Veterans with PTSD related to MST.
Time Frame: Baseline; Mid-Treatment (TSY, 5 weeks: CPT, 6 weeks); 2-Weeks Post-Treatment; 3-Months Post-Treatment

Participants in the TSY group will show statistically and clinically meaningful improvements in quality of life and social functioning (PROMIS measures) compared to CPT group results.

- PROMIS v2.0 (Short Forms 4a) Ability to Participate in Social Roles and Activities, Social Isolation, Satisfaction with Social Roles and Activities, and Emotional Support; VR12/SF12.

Baseline; Mid-Treatment (TSY, 5 weeks: CPT, 6 weeks); 2-Weeks Post-Treatment; 3-Months Post-Treatment
To evaluate the effectiveness of TSY as compared to CPT over time in alterations in C-reactive proteins.
Time Frame: Baseline; 2-Weeks Post-Treatment; 3-Months Post-Treatment

Participants in the TSY group will show statistically and clinically meaningful changes in biological stress response (C-reactive protein).

Alterations in C-reactive protein is associated with symptoms that commonly co-occur with PTSD, including depressive symptoms, fatigue, chronic tissue inflammation, and enhanced sensitivity to pain.

-Blood samples will collected and analyzed by a laboratory.

Baseline; 2-Weeks Post-Treatment; 3-Months Post-Treatment
To evaluate the effectiveness of TSY as compared to CPT over time in elevations in pro-inflammatory cytokines.
Time Frame: Baseline; 2-Weeks Post-Treatment; 3-Months Post-Treatment

Participants in the TSY group will show statistically and clinically meaningful changes in biological stress response (inflammatory cytokines).

Elevations in pro-inflammatory cytokines, including IL-6 and IL-10, have been shown to correlate with increasing pain intensity in patients with chronic pain, psychological stress, and PTSD. IL-6 has been shown to act as a messenger relaying chemotactic peripheral immune signals to the central nervous system. In addition, IL-6 has been established as part of the biochemical sleep regulatory process.

-Blood samples will collected and analyzed by a laboratory.

Baseline; 2-Weeks Post-Treatment; 3-Months Post-Treatment
To evaluate the effectiveness of TSY as compared to CPT over time in parasympathetic and sympathetic nervous systems
Time Frame: Baseline; 2-Weeks Post-Treatment; 3-Months Post-Treatment

Participants in the TSY group will show statistically and clinically meaningful changes in biological stress response (nervous system).

Heart rate variability reflects the central nervous system's ability to respond immediately to fluctuations in blood pressure occurring with each beat. Decreased heart rate variability has been correlated with morbidity and mortality from diverse diseases, including anxiety and depression and cardiovascular disease.

- Electrocardiographic monitoring of the R-R interval using portable recording device.

Baseline; 2-Weeks Post-Treatment; 3-Months Post-Treatment
To evaluate the effectiveness of TSY as compared to CPT over time in autonomic electrocardiogram markers (QT interval).
Time Frame: Baseline; 2-Weeks Post-Treatment; 3-Months Post-Treatment

Participants in the TSY group will show statistically and clinically meaningful changes in biological stress response (autonomic ECG markers).

- 12-lead electrocardiogram

Baseline; 2-Weeks Post-Treatment; 3-Months Post-Treatment
To evaluate the effectiveness of TSY as compared to CPT over time in levels of fear and anxiety.
Time Frame: Baseline; 2-Weeks Post-Treatment; 3-Months Post-Treatment

Participants in the TSY group will show statistically and clinically meaningful changes in biological stress response (acoustic startle response).

- BIOPAC MP150 Psychophysiological Recording System

Dark-enhanced startle is an ecologically valid psychophysiological paradigm for assessing contextual levels of fear and anxiety. Dark-enhanced startle is a laboratory analogue of sustained anxiety and represents a clinically useful tool for assessing anxiety-like behaviors and hyperarousal as they relate to symptom severity.

Baseline; 2-Weeks Post-Treatment; 3-Months Post-Treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Ursula Ann Kelly, PhD MSN BA, Atlanta VA Medical and Rehab Center, Decatur, GA

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2016

Primary Completion (Actual)

February 26, 2021

Study Completion (Actual)

September 30, 2021

Study Registration Dates

First Submitted

December 16, 2015

First Submitted That Met QC Criteria

December 23, 2015

First Posted (Estimate)

December 29, 2015

Study Record Updates

Last Update Posted (Actual)

October 14, 2022

Last Update Submitted That Met QC Criteria

October 11, 2022

Last Verified

October 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stress Disorders, Post-traumatic

Clinical Trials on Trauma Center Trauma Sensitive Yoga Intervention (TCTSY)

3
Subscribe